Cargando…

FLT3-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk Stratification

SIMPLE SUMMARY: Around 12–38% of acute promyelocytic leukemia (APL) patients carry the FLT3-ITD mutation, which has been associated with several poor-prognosis indicators such as high white blood cell counts, M3v variant morphology, and the bcr3 isoform. We aimed to retrospectively study the impact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Andrew Y., Kashanian, Sarah M., Hambley, Bryan C., Zacholski, Kyle, Duong, Vu H., El Chaer, Firas, Holtzman, Noa G., Gojo, Ivana, Webster, Jonathan A., Norsworthy, Kelly J., Smith, Bruce Douglas, DeZern, Amy E., Levis, Mark J., Baer, Maria R., Kamangar, Farin, Ghiaur, Gabriel, Emadi, Ashkan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003857/ https://www.ncbi.nlm.nih.gov/pubmed/33800974 http://dx.doi.org/10.3390/biology10030243

Ejemplares similares

Increased body mass index is a risk factor for acute promyelocytic leukemia
por: Kashanian, Sarah M., et al.
Publicado: (2021)

Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3
por: Nagai, Kozo, et al.
Publicado: (2018)

Coagulopathy in Acute Promyelocytic Leukemia: Can We Go Beyond Supportive Care?
por: Hambley, Bryan C., et al.
Publicado: (2021)

Potential Effects of the FLT3-ITD Mutation on Chemotherapy Response and Prognosis of Acute Promyelocytic Leukemia
por: Song, Yu-hua, et al.
Publicado: (2021)

Association between FLT3-ITD and additional chromosomal abnormalities in the prognosis of acute promyelocytic leukemia
por: Vu, Minh Phuong, et al.
Publicado: (2022)

Vitamin and Mineral Supplements: Do We Really Need Them?
por: Kamangar, Farin, et al.
Publicado: (2012)

Promyelocytic sarcoma of the right humerus: an unusual clinical presentation with unique diagnostic and treatment considerations
por: Sawhney, Sameer, et al.
Publicado: (2017)

Impact of FLT3-ITD Insertion Length on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study
por: Corley, Elizabeth M., et al.
Publicado: (2022)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
por: Lee, Lauren Y., et al.
Publicado: (2021)

Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic features
por: Sidhom, John-William, et al.
Publicado: (2021)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

Arsenic trioxide induces autophagic degradation of the FLT3-ITD mutated protein in FLT3-ITD acute myeloid leukemia cells
por: Liu, Xiao-Jian, et al.
Publicado: (2020)

The Coagulopathy of Acute Promyelocytic Leukemia: An Updated Review of Pathophysiology, Risk Stratification, and Clinical Management
por: Hermsen, Jack, et al.
Publicado: (2023)

FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation
por: Zhu, Ruiqi, et al.
Publicado: (2021)

Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients
por: Hong, Seung-Dok, et al.
Publicado: (2011)

Early Death in Two Patients with Acute Promyelocytic Leukemia Presenting the bcr3 Isoform, FLT3-ITD Mutation, and Elevated WT1 Level
por: Greco, Marianna, et al.
Publicado: (2013)

Reverse Pseudohyperkalemia: An Important Clinical Entity in Chronic Lymphocytic Leukemia
por: Mansoor, Sahar, et al.
Publicado: (2015)

RUNX1 cooperates with FLT3-ITD to induce leukemia
por: Behrens, Kira, et al.
Publicado: (2017)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
por: Iannotta, R., et al.
Publicado: (2022)

The GSK3β/Mcl-1 axis is regulated by both FLT3-ITD and Axl and determines the apoptosis induction abilities of FLT3-ITD inhibitors
por: Qiu, Yang, et al.
Publicado: (2023)

Maturation State-Specific Alternative Splicing in FLT3-ITD and NPM1 Mutated AML
por: Wojtuszkiewicz, Anna, et al.
Publicado: (2021)

How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia
por: Haage, Tobias R., et al.
Publicado: (2023)

Wild‐type FLT3 and FLT3 ITD exhibit similar ligand‐induced internalization characteristics
por: Kellner, Fabienne, et al.
Publicado: (2020)

Overcoming AC220 resistance of FLT3-ITD by SAR302503
por: Kesarwani, M, et al.
Publicado: (2013)

Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia
por: Burchert, Andreas
Publicado: (2021)

MicroRNA networks in FLT3-ITD acute myeloid leukemia
por: Hoang, Dinh Hoa, et al.
Publicado: (2022)

Lack of FLT3-ITD in Tunisian childhood acute lymphoblastic leukemia
por: Frikha, Rim, et al.
Publicado: (2022)

FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML
por: Kivioja, Jarno, et al.
Publicado: (2021)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
por: Xu, Dan, et al.
Publicado: (2022)

Charting a course through the acute promyelocytic leukemia (APL)-like nebula: the enigmatic cousins of APL
por: Ghiaur, Alexandra, et al.
Publicado: (2023)

FLT3/ITD associated with an immature immunophenotype in PML-RARα leukemia
por: Takenokuchi, Mariko, et al.
Publicado: (2012)

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia
por: Pillinger, Genevra, et al.
Publicado: (2015)

Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML
por: Vachhani, Pankit, et al.
Publicado: (2016)

DOCK2: A novel FLT3/ITD leukemia drug target
por: Wu, Min, et al.
Publicado: (2017)

Feature genes predicting the FLT3/ITD mutation in acute myeloid leukemia
por: LI, CHENGLONG, et al.
Publicado: (2016)

Gab2 is Essential for Transformation by FLT3-ITD in Acute Myeloid Leukemia
por: Sies, Katharina, et al.
Publicado: (2019)

Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

Cigarette smoke exposure accelerates AML progression in FLT3-ITD models
por: Figueroa, Mary, et al.
Publicado: (2023)

Understanding the Role of Activation Loop Mutants in Drug Efficacy for FLT3-ITD
por: Kazi, Julhash U., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2p6itnmir545vnt7ehcsclidt8